BB 1511
Alternative Names: BB-1511Latest Information Update: 29 Sep 2023
At a glance
- Originator Blueberry Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Atopic dermatitis
- Preclinical Unspecified
Most Recent Events
- 28 Aug 2023 Phase-I/II clinical trials in Atopic dermatitis (Topical), prior to August 2023 (Blueberry therapeutics pipeline, August 2023)
- 28 Aug 2023 Preclinical trials in Unspecified in United Kingdom (Topical), (Blueberry therapeutics pipeline, August 2023)